Metabolic Health: Key Factors for Obesity & Diabetes

Discover effective methods to address obesity and diabetes that affect your metabolic health and enhance your health journey.

Abstract

Obesity is a complex, chronic disease, not a simple matter of willpower. It serves as the root cause of many prevalent cardiometabolic conditions, including type 2 diabetes and cardiovascular disease. In this educational post, I, Dr. Alex Jimenez, will guide you through the intricate physiological connections between these conditions, highlighting chronic inflammation, mitochondrial dysfunction, and hormonal dysregulation as key overlapping mechanisms. Drawing on the latest evidence-based research, we will explore how these conditions are deeply intertwined and examine detailed case studies illustrating how modern treatments, including continuous glucose monitors (CGMs) and advanced medications such as semaglutide and tirzepatide, are revolutionizing patient care. A key focus will be on how treating obesity serves as a cornerstone for managing and often reversing its related comorbidities. I’ll explain our unique, multidisciplinary approach at Injury Medical Clinic PA, where we combine medical oversight by our Medical Director, Dr. Maria Guadalupe Cardenas, MD, with functional medicine and integrative chiropractic care to provide a holistic, comprehensive treatment journey for our patients.

Our Integrative Team: A Collaborative Approach to Wellness

Hello, I am Dr. Alex Jimenez. With my credentials as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), Board-Certified Family Nurse Practitioner (FNP-BC), and certifications in Functional Medicine (CFMP, IFMCP), Applied Traumatology (ATN), and Cranial-Sacral Techniques (CCST), my career has been dedicated to exploring the root causes of chronic illness. At our practice, Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, we have built a practice on the foundation of integrative care, where we don’t just treat symptoms; we investigate the root causes of dysfunction.

A cornerstone of our clinic’s success is our collaborative model. I am privileged to work alongside our esteemed Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933). Dr. Cardenas is Board Certified in Internal Medicine and brings over 40 years of invaluable clinical experience to our team. Her medical expertise and oversight are essential to our practice, allowing us to offer chiropractic care, functional medicine, rehabilitation, and personal injury care under one roof. This multidisciplinary setup is essential for treating complex, interconnected chronic diseases and ensuring our patients get comprehensive care that combines conventional medicine with innovative therapies. Together, we create a synergistic treatment strategy that addresses the patient as a whole person.

Today, I want to take you on a journey into the deep-seated connections between three of the most significant health challenges of our time: obesity, type 2 diabetes, and cardiovascular disease.

The Root of the Problem: Rethinking Obesity

For too long, the prevailing narrative has been that conditions like diabetes and cardiovascular disease are distinct problems, often treated in isolation. Insurers and even some healthcare providers have historically viewed obesity differently, sometimes dismissing treatments for it as “vanity.” This perspective fundamentally misunderstands the science. The truth is, obesity is a chronic, progressive, and relapsing disease that often serves as the underlying cause—the very roots—of many other metabolic and cardiovascular disorders we treat daily.

Imagine a tree. The branches and leaves—hypertension, dyslipidemia, and metabolic syndrome—are the visible symptoms we manage with numerous medications. However, the roots anchoring and feeding this tree are often the dysregulation caused by obesity.

The Biology of Weight Regulation

Our bodies have incredibly sophisticated, tightly regulated systems. Surprisingly, body weight is also tightly regulated. A groundbreaking shift in our understanding is this: Overeating doesn’t necessarily cause obesity; rather, obesity causes overeating. Before a noticeable increase in fat tissue (adiposity), there is often a dysregulation in the endocrine system—specifically, the hormones that control hunger and satiety.

Here’s how it works:

1. The First Hit: Something triggers the “on” switch for obesity. This could be a genetic predisposition activated by obesogenic medications, exposure to endocrine-disrupting chemicals, chronic stress, or poor sleep.
2. Hormonal Imbalance: Once activated, the body’s hormonal balance shifts. Ghrelin, the “hunger hormone,” increases, while satiety hormones like leptin become less effective (a state known as leptin resistance). This biological shift drives increased hunger and food intake.
3. Increased Adiposity: Over time, this hormonally driven overeating leads to an accumulation of fat mass.
4. The Second Hit: The brain starts to defend this new, higher body weight as its normal set point. This phenomenon, known as metabolic adaptation, is driven by inflammation in the hypothalamus, the brain’s control center for appetite and energy expenditure.

This is why weight regain is so common after weight loss. This metabolic adaptation is a powerful pathological process, not a personal failing.

The Pathophysiological Overlap: A Three-Way Intersection

To truly appreciate the need for an integrative approach, we must understand how the pathophysiology of obesity, diabetes, and cardiovascular disease overlap. The American Diabetes Association has established clear goals for diabetes management that go beyond just controlling blood sugar; they include treating obesity, achieving glycemic targets, and reducing the risk of cardiovascular, liver, and kidney disease. By effectively treating obesity, we simultaneously make significant strides toward achieving all these other critical health goals.

The Path to Type 2 Diabetes

The progression from a healthy metabolism to type 2 diabetes is a well-documented journey that typically unfolds over several years.

• It begins with insulin resistance, where the body’s cells no longer respond efficiently to insulin.
• The pancreatic beta cells compensate by producing more insulin to keep blood sugar in check.
• Eventually, these cells become exhausted and can’t keep up, leading to defective insulin secretion.
• Blood sugar levels begin to rise, first to the level of prediabetes and finally to type 2 diabetes.

Recent research has expanded this view, showing that diabetes is a systemic issue extending far beyond the pancreas. It involves chronic inflammation, an imbalanced gut microbiome (dysbiosis), and mitochondrial dysfunction. Recognizing this continuum is critical because treating obesity early can profoundly alter or even prevent the progression to full-blown diabetes.

The Cardiovascular Connection

Atherosclerosis, the hardening and narrowing of arteries, is the common denominator for most cardiovascular diseases. And what is the common denominator for atherosclerosis? You guessed it: inflammation. This chronic, low-grade inflammation directly impacts a crucial molecule called nitric oxide (NO).

• In a healthy state, nitric oxide promotes vasodilation (widening of blood vessels), reduces inflammation, and prevents oxidative stress.
• In disease, nitric oxide production is impaired. This leads to a cascade of negative effects, including increased platelet aggregation (clotting), increased inflammation, endothelial dysfunction, and decreased glucose tolerance. These are the same dysfunctions we see in the development of type 2 diabetes.

The Triad of Dysfunction

When we put all three conditions together—obesity, diabetes, and cardiovascular disease—a clear picture emerges. The core overlapping mechanisms are:

• Chronic Inflammation: Originating in excess adipose tissue.
• Oxidative Stress: An imbalance between free radicals and antioxidants.
• Insulin Resistance: A key feature linking metabolic and cardiovascular health.
• Lipotoxicity: The damaging effect of excess fats accumulating in non-adipose tissues.
• Mitochondrial Dysfunction: Inefficient cellular powerhouses.

These factors create a prothrombotic (clot-promoting) and pro-atherogenic (plaque-promoting) environment, directly linking obesity and diabetes to cardiovascular events.

An Integrative Framework for Treatment

Given this profound overlap, it makes sense that the foundational treatment strategies for all three conditions are remarkably similar. Major clinical guidelines for obesity, diabetes, and cardiovascular disease all recommend comprehensive lifestyle changes as the cornerstone of therapy. However, with obesity, there is often an expectation for patients to “fail” lifestyle changes before initiating pharmacotherapy. This is a flawed approach. Research clearly shows that most individuals with obesity have already made multiple, concerted efforts to lose weight, only to be thwarted by metabolic adaptation. Anti-obesity medications are not a crutch; they are tools that directly target the disease’s underlying pathophysiology, just as metformin targets insulin resistance in diabetes.

The Power of Chiropractic and Functional Medicine

This is where our integrative model at Injury Medical Clinic shines. My role as a chiropractor and functional medicine practitioner is to address the foundational lifestyle factors and musculoskeletal health that are critical for success.

• Chiropractic Care: Chronic pain, particularly in the back, hips, and knees, is a major barrier to physical activity. By using spinal adjustments, mobilization techniques, and soft tissue therapies, we can reduce pain, improve joint function, and enhance mobility. This allows patients to engage in the very activity essential to improving insulin sensitivity and cardiovascular health. Proper alignment and nervous system function, core focuses of chiropractic, also support the body’s overall ability to regulate itself, helping shift the body from a stressed “fight-or-flight” state to a healing “rest-and-digest” state.
• Functional Medicine: We take a deep dive into the individual’s unique biochemistry. Through advanced testing, we can identify specific drivers of inflammation, gut dysbiosis, nutrient deficiencies, and hormonal imbalances. This allows us to create personalized nutrition plans, recommend targeted supplementation, and develop stress management strategies that address the root causes of their metabolic dysfunction.

Dr. Cardenas provides the essential medical oversight, managing pharmacotherapy for diabetes and hypertension and collaborating with us to ensure our lifestyle interventions are safe and effective. This team-based approach allows us to attack the problem from all sides.

---

Chiropractic Care & Metabolism *The Hidden Link*- Video

---

Case Studies in Modern, Integrated Care

To illustrate these concepts, let’s explore the journeys of three different patients. My purpose in sharing these case studies is to illuminate the profound benefits of treating obesity early and aggressively, the critical factors that influence our treatment decisions, and the chronic, progressive nature of these conditions, which demand long-term, sustained management.

Case Study 1: Stephen’s Journey with Prediabetes

Stephen, a 24-year-old male, came to my office for a follow-up on his prediabetes and for help with weight management. His opening words were filled with frustration: “I’ve been trying to lose weight, but it’s just not working.” Six months prior, he had been diagnosed with prediabetes, marked by a hemoglobin A1c of 5.8%.

A thorough weight history revealed his weight gain began at age 13 during a period of significant stress. His family history was strong for obesity, cardiovascular disease, and type 2 diabetes. His exam showed a BMI of 32.1 (Class 1 Obesity), a 41-inch waist circumference indicating visceral adiposity, and acanthosis nigricans—a common skin marker of insulin resistance.

I explained the importance of clinically significant weight loss, showing him that a 10- 15% weight loss is often needed to reverse prediabetes. Based on his profile—young, motivated, and needing significant weight loss—we discussed advanced therapeutic options. The landmark SURMOUNT-1 trial, published in 2022, showed that Tirzepatide helped individuals achieve an average weight loss of nearly 21%.

After a thorough discussion, Stephen elected to start Tirzepatide alongside a comprehensive four-pillar plan: Nutrition, Physical Activity, Behavioral Health, and Medical Management. Frequent follow-ups were critical. One year later, the results were remarkable. He had lost 50 pounds (a 20% total body weight loss), his BMI dropped to 25.7, and his A1c was 5.4%, completely reversing his prediabetes. Stephen’s journey is a powerful testament to what is possible with a modern, integrated, and aggressive approach.

Case Study 2: Victoria’s Journey Through Menopause and Diabetes

Victoria, a 52-year-old female, presented with prediabetes, recent weight gain, and classic menopausal symptoms like hot flashes and poor sleep. The menopause transition is a period of profound metabolic shifts, including increased insulin resistance and a rise in visceral fat, which amplifies cardiovascular risk. Her labs confirmed our concerns: her A1C had climbed to 7.3%, officially diagnosing her with type 2 diabetes.

Our plan targeted four key areas: nutrition, physical activity, health behaviors, and medical management. Victoria chose to try a Continuous Glucose Monitor (CGM), a wearable device that tracks glucose in real time. The CGM data was eye-opening, helping her see the direct impact of food choices on her blood sugar. She also started menopause hormone therapy. However, a month later, she was frustrated with minimal weight change.

Research shows that combining semaglutide, a GLP-1 receptor agonist, with hormone therapy leads to greater weight reduction. After discussing the benefits, Victoria agreed to start semaglutide. One year later, she had lost 25 pounds, her BMI had dropped from 31.8 to 27.5, her A1C had improved, and her cholesterol levels had normalized. By treating her obesity as the central issue, we successfully improved her diabetes and reduced her cardiovascular risk factors.

Case Study 3: Banny’s Battle with Long-Standing Diabetes and Heart Disease

Banny, a 64-year-old man, had a 25-year history of type 2 diabetes, a prior heart attack, and a BMI of 36 (Class 2 Obesity). It was essential to delve into his eating behaviors, and he admitted to cravings and portion control issues. Although his A1C was at goal, his history of cardiovascular disease made him a prime candidate for a medication that could do more.

Semaglutide was the ideal choice. Cardiovascular outcome trials have demonstrated that this medication significantly reduces cardiovascular risk in patients with both diabetes and known heart disease. His initial labs also revealed a slightly elevated liver enzyme. Using the FIB-4 score, we determined he was at high risk for Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), a silent condition common in people with obesity and diabetes. I immediately referred him to a gastroenterologist, showcasing our collaborative approach.

At his one-year follow-up, Banny had lost 23 pounds, and his A1C had improved to 5.9%, but he was frustrated by a weight-loss plateau. To address this, we added a second medication, topiramate, to help control cravings. For a patient like Banny, our integrative model provides multifaceted support. Functional medicine helps address his stress, while chiropractic care maintains his musculoskeletal health, allowing him to remain active in his physically demanding job without pain.

The Chronic Nature of Obesity and the Pathology of Weight Regain

Finally, we must recognize that obesity is a chronic disease requiring long-term management. When a person with obesity loses weight, the brain’s defense mechanisms kick in: energy expenditure decreases, the hunger hormone ghrelin increases, and satiety hormones decrease. This creates an intense biological drive to regain the lost weight.

The STEP 1 Extension Trial demonstrated this clearly. When participants stopped taking semaglutide, significant weight regain was apparent within just four weeks. What’s more, their blood pressure and HbA1c levels began to rise after stopping the medication. This is powerful proof that treating obesity has a protective effect on cardiometabolic health, and this protection is lost when treatment is withdrawn.

At Injury Medical Clinic, our integrated team, led by the collaborative expertise of Dr. Cardenas and me, is committed to providing this necessary long-term care. We combine advanced medical treatments with sustained support through chiropractic adjustments, functional nutrition, and rehabilitation to help our patients lose weight, restore metabolic function, reduce disease risk, and reclaim their quality of life for the long haul.

References

1. American Diabetes Association Professional Practice Committee. (2024). 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S141–S158.
2. Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., Michos, E. D., Miedema, M. D., Muñoz, D., Smith, S. C., Jr, Virani, S. S., Williams, K. A., Sr, Yeboah, J., & Ziaeian, B. (2019). 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140(11), e596–e646.
3. Bays, H. E., McCarthy, W., Christensen, S., Tondt, J., & Karupari, N. (2022). Obesity and cardiometabolic disease: A narrative review of the science and art of implementing lifestyle and pharmacologic therapies. Journal of Clinical Lipidology, 16(5), 575–601.
4. ElSayed, N. A., Aleppo, G., Aroda, V. R., et al. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S158–S178.
5. ElSayed, N. A., Aleppo, G., Aroda, V. R., et al. (2024). 10. Cardiovascular disease and risk management: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S179–S218.
6. Gabbay, R. A., & Zonszein, J. (2024). The latest in obesity and diabetes: Case-based treatment considerations. Endocrine Society.
7. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.
8. Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., Loria, C. M., Millen, B. E., Nonas, C. A., Pi-Sunyer, F. X., Stevens, J., Wadden, T. A., & Wolfe, B. M. (2014). 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation, 129(25_suppl_2), S102–S138.
9. Lin, X., & Li, H. (2021). Obesity: Epidemiology, Pathophysiology, and Therapeutics. Frontiers in Endocrinology, 12, 706978.
10. Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Tsilchorozidou, T., Wadden, T. A., & STEP 1 Study Group. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564.

Disclaimer: Dr. Jimenez and Dr. Golden have disclosed any potential conflicts of interest, and they have been appropriately mitigated.

SEO Tags: Obesity Treatment, Type 2 Diabetes, Cardiovascular Disease, Integrative Chiropractic Care, Functional Medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso TX, Chronic Inflammation, Metabolic Adaptation, Weight Regain, GLP-1 Agonists, Tirzepatide, Semaglutide, Nitric Oxide, Insulin Resistance, Cardiometabolic Health, Multidisciplinary Clinic, Prediabetes Reversal, Case Study, SURMOUNT-1, A1c, Continuous Glucose Monitor, CGM, Menopause, MASLD, Liver Disease, Holistic Healthcare, Medical Weight Loss